A Phase I, Open-Label Study to Assess the Effect of Escalating Doses of Cyclophosphamide on the Engraftment of SB-728-T in Aviremic HIV-Infected Subjects on HAART

Trial Profile

A Phase I, Open-Label Study to Assess the Effect of Escalating Doses of Cyclophosphamide on the Engraftment of SB-728-T in Aviremic HIV-Infected Subjects on HAART

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs SB 728 T (Primary) ; Cyclophosphamide
  • Indications HIV infections
  • Focus Adverse reactions
  • Sponsors Sangamo Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Jan 2017 According to a Sangamo Therapeutics media release, this trial was originally conducted by Sangamo BioSciences but later on this company's name changed to Sangamo Therapeutics.
    • 02 May 2016 Data from cohort 3 expected in the second half of 2016, according to a Sangamo BioSciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top